Business Wire

The Open Group: Hybrid Big Data Technologies Developed From €4.5M European Union Research Project Enter Final Industrial Evaluations

Share

The Open Group, the vendor-neutral technology consortium, and the University of York today announced a partnership with a consortium of leading European research organizations, software developers, and industrial big data users. Together, they will make hybrid big data accessible and easy to integrate within new applications and services through developing and evolving next generation technologies.

With support from the European Union, the Polyglot and Hybrid Persistence Architectures for Big Data Analytics (TYPHON) project has already invested €4.5 million (US$5.3 million) into advanced technology development. This funding has enabled the rapid creation of applications that bridge the many formats and architectures used to store data today. The integrated platform is currently undergoing first deployments within major organizations across the Telecom, Banking, Automotive, and Aerospace industries, and is being made widely available in open source format. By implementing the new technologies, organizations are able to enhance the productivity of their data architects, reduce development time and costs, and deliver new applications and services that make full use of existing big data stores.

Today’s development teams face substantial challenges when it comes to ensuring hybrid big data applications and services are designed coherently, which requires capturing a range of different formats that data is held within. To overcome these complexities, the TYPHON project has built a set of tools for developing, querying, evolving, analyzing, and monitoring hybrid big data polystores. These polystores readily combine numerous types of underlying storage technologies, including relational, graph-based, document-based, natural language, and big data islands.

David Lounsbury, Chief Digital Officer, The Open Group said: “The TYPHON project has brought together a range of industry experts who have collaborated to streamline the time intensive process of implementing intricate big data solutions. By connecting many different storage formats, the new technologies enable developers to deliver applications capable of effectively utilizing big data assets within organizations. The Open Group has a long-standing history of working with the University of York on complex systems. Together, we can provide the expertise and guidance needed to drive these technologies through final industrial evaluations.”

The advanced tools provide big data systems developers with:

  • Technologies for designing hybrid polystores, taking into account the structure of the data, the availability, partitioning, and consistency requirements of different subsets of the data, and the available deployment resources
  • Novel algorithms for transforming hybrid polystore design models into preconfigured optimized virtual machines which can be deployed on cloud infrastructure
  • An extensible high-level language for querying and modifying data stored in hybrid polystores, as well as capabilities for translating high-level queries into efficient native queries
  • A high-performance framework for publishing and processing data access and updating events to facilitate real-time monitoring and predictive analytics
  • Technologies for evolving the organization and distribution of data in hybrid polystores, along with tools for monitoring use of polystores for enhanced evolution

Coordinated by The Open Group with technical leadership from the University of York, which has directed the advanced research, the TYPHON consortium includes:

“With the availability of the TYPHON Modelling Language, Query Language, Deployment Language, and tools for creating, monitoring, and evolving new hybrid big data polystores, software developers can now rapidly create next generation applications and systems,” said Professor Dimitris Kolovos, University of York. “Through addressing key industry challenges, the TYPHON project is dedicated to ensuring hybrid big data solutions are designed, assembled, and configured consistently - ultimately enabling organizations to unlock the power of data.”

The technological advances and innovations resulting from the TYPHON project, as well as the final versions of the technologies in open source format are publically available via the project website: www.typhon-project.org

The TYPHON project receives funding under the European Union Horizon 2020 Research and Innovation Programme, an initiative of the European Community created to foster European research and the development of new technologies, applications, and industries.

-ENDS-

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org.

About the University of York

The Department of Computer Science at the University of York prepares graduates for the workplace at all levels through close collaboration with industry. The majority of the research work carried out has been classed as world-leading or internationally excellent and is focused around seven themes which align our academic strengths to best meet the greater scientific, social and environmental challenges of our time. Research teams work across disciplines within academia and industry with a strong focus placed on transforming research results into tangible solutions for industry. Further information on the University of York can be found at www.cs.york.ac.uk.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Jenny Morris
Hotwire PR (on behalf of The Open Group)
+44 (0)7393465529
UKOpengroup@hotwirepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye